This study evaluated the possible contribution of gap junctions to the nitric oxide (NO)-and endothelium-derived hyperpolarizing factor (EDHF)-mediated responses elicited by bradykinin in bovine pulmonary supernumerary arteries. In artery rings with an intact endothelium and treated with the cyclo-oxygenase inhibitor indomethacin (10 µM), bradykinin (100 pM-1 µM) produced a concentration-dependent relaxation [klogEC 50 (pEC 50 ), 9.6p0.2 ; maximum relaxation (R max ), 89.7p14.8 % ; n l 6]. The NO synthase inhibitor N G -nitro-L-arginine methyl ester (L-NAME ; 100 µM) and the NO scavenger hydroxocobalamin (200 µM) each produced a rightward shift in the bradykinin concentration-response curve [pEC 50 : L-NAME, 8.9p0.1 (n l 6; P 0.01) ; hydroxocobalamin, 8.3p0.2, (n l 6; P 0.001)]. However, the soluble guanylate cyclase inhibitor ODQ (1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one ; 10 µM) did not significantly alter the response to bradykinin (pEC 50 9.4p0.2 ; n l 9). The gap junction inhibitor carbenoxolone (100 µM) did not affect the relaxation produced by bradykinin (pEC 50 , 9.7p0.1 ; R max , 100p3.2 % ; n l 6), but it significantly depressed R max when L-NAME, hydroxocobalamin or ODQ was present. Further, carbenoxolone produced a rightward shift in the bradykinin concentration-response curve in the presence of ODQ (8.4p0.1 ; n l 6, P 0.01). The data suggest that, in bovine pulmonary supernumerary arteries, gap junctions may, in part, facilitate the EDHF-mediated response, but not the NO-mediated response, to bradykinin. However, the additional involvement of an unidentified endothelial relaxing factor cannot be excluded.
Involvement of gap junctions in bradykinin-
induced relaxation of bovine pulmonary supernumerary arteries before and after inhibition of nitric oxide/guanylate cyclase
INTRODUCTION
We have reported that an endothelium-derived hyperpolarizing factor (EDHF)-like mechanism can mediate the vasorelaxation induced by bradykinin in bovine pulmonary supernumerary arteries when nitric oxide (NO) has been removed or when guanylate cyclase is inhibited [1] . In blood vessels from a number of vascular such as ATP, cyclic nucleotides and InsP $ , can diffuse [6] . Ultrastructural studies show that these channels occur in groups of several hundred in the plasma membrane, giving the appearance of a plaque [7] . Each channel is formed from two hemichannels, one donated from each of the adjoining cells. Each hemichannel is constructed from six connexin proteins, and channels may be constructed from two hemichannels containing the same set of six connexin proteins (homotypic) or two different sets of connexin subtypes (heterotypic). Hemichannels may also be constructed from two or more connexin subtypes (heterotropic) [8] . Connexin subtypes are classified according to molecular mass, and in the blood vessels that have been investigated the connexin subtypes Cx37 (connexin of 37 kDa), Cx40 and Cx43 are present in both endothelium and smooth muscle [9, 10] .
The present study aimed to determine the involvement of gap junctions in the bradykinin-induced relaxation of supernumerary arteries. The study used the putative gap junction inhibitor carbenoxolone, a water-soluble salt of 18β-glycyrrhetinic acid that is thought to inhibit junctional connections by lowering the phosphorylation state of the connexin proteins [11] .
MATERIALS AND METHODS

Tissue preparation
Bovine lungs were obtained from a local abattoir within 30 min of slaughter. Ring segments of the supernumerary artery (external diameter 0.5-1.0 mm) were dissected from the lung and freed of surrounding connective tissue. Care was taken not to damage the luminal surface of the preparation. The vessels were suspended between two stainless steel wire hooks in 10 ml Linton vessel chambers containing Krebs\Henseleit physiological salt solution (PSS) of the following composition (mM) : NaCl (119), KCl (4.7), NaHCO
2), CaCl (2.5) and glucose (11.1). Tissues were maintained at 37 mC under a tension of 1.5 g, and gassed with a mixture of 95 % O # \5% CO # . Changes in isometric tension were measured by a force-displacement transducer (Grass Instruments, FT03). The output from the transducer was amplified and displayed on a Lectromed MTR8P chart recorder.
Experimental protocols
Following an equilibration period of 60 min, the artery rings were constricted with a submaximal concentration of the thromboxane A # mimetic U46619 (0.3 µM). The endothelium-dependent vasodilator bradykinin (100 nM) was then used to indicate that the endothelium was intact. This was verified at the beginning of each experiment. Tissues displaying less than 70 % relaxation to bradykinin were discarded. All tissues were washed with PSS over a period of 30 min and then pretreated with the angiotensin-converting enzyme inhibitor captopril (10 µM) for 30 min to prevent bradykinin degradation as well as with the cyclo-oxygenase inhibitor indomethacin (10 µM) in order to exclude the possible involvement of cyclo-oxygenase-derived products in the relaxant response.
Studies examining the effects of gap junction inhibition on the NO-and EDHFmediated relaxation to bradykinin
To assess the role of gap junctions in the NO-mediated relaxation induced by bradykinin in bovine pulmonary supernumerary arteries, tissues were either left untreated (control) or treated with carbenoxolone (100 µM). Similarly, to evaluate the role of gap junctions in facilitating EDHF-mediated relaxation, tissues were pretreated with the NO synthase inhibitor N G -nitro-L-arginine methyl ester (L-NAME ; 100 µM), the NO scavenger hydroxocobalamin (200 µM) [12] or the soluble guanylate cyclase inhibitor ODQ (1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one ; 10 µM) [13] alone or in combination with carbenoxolone (100 µM). After a 30 min incubation, all artery rings were contracted with U46619 (0.3 µM). Upon reaching a steady-state level of contraction, bradykinin was added to the organ baths cumulatively in half-log increments from 100 pM to 1 µM in order to construct a concentration-response curve for relaxation to bradykinin. 
Statistics
Chemicals
Bradykinin (acetate salt), captopril, L-NAME, ODQ, indomethacin (dissolved in absolute ethanol), hydroxocobalamin (acetate salt ; dissolved in distilled water at 90 mC on the day of the experiment) and carbenoxolone (dissolved in distilled water immediately before use) were purchased from Sigma Chemical Co. U46619 (9,11-dideoxy-11α,9α-epoxymethano-prostaglandin F # α ; Affiniti Research Products Limited) was dissolved in absolute ethanol and stored at k20 mC for up to 6 months as a 1 mM stock solution. Unless otherwise stated, compounds were dissolved in distilled water. Fresh dilutions of stock solutions were made up in PSS at the beginning of each experiment.
RESULTS
Effect of carbenoxolone on bradykinininduced relaxation in endothelium-intact supernumerary arteries
In bovine pulmonary supernumerary arteries with an intact endothelium contracted with U46619 (0.3 µM), bradykinin (100 pM-1 µM) produced a concentrationdependent relaxation, which was unaffected by carbenoxolone ( Figure 1 , Table 1 ). Indomethacin (10 µM) was present in all experiments. U46619 was used at a concentration of 0.3 µM. Data are meanspS.E.M. for the numbers of animals indicated. Student's t test was used to indicate significant differences between (a) controls and arteries treated with L-NAME, hydroxocobalamin or ODQ (*P 0.01, **P 0.001), and (b) before and after treatment with carbenoxolone ( †P 0.05, † †P 0.01). 
Effects of carbenoxolone on the bradykinininduced relaxation of supernumerary arteries in the presence of L-NAME, hydroxocobalamin or ODQ
The NO synthase inhibitor L-NAME (100 µM) and the NO scavenger hydroxocobalamin (200 µM) reduced tissue sensitivity to bradykinin without affecting R max . In contrast, the soluble guanylate cyclase inhibitor ODQ (10 µM) did not significantly alter tissue sensitivity to bradykinin or R max ( Figure 2 , Table 1 ).
In the presence of L-NAME, hydroxocobalamin or ODQ, carbenoxolone significantly reduced R max produced by bradykinin. Additionally, in the presence of ODQ, carbenoxolone resulted in a decrease in tissue sensitivity to bradykinin (Figure 2, Table 1 ).
DISCUSSION
In bovine pulmonary supernumerary arteries in the absence of any inhibitors of the NO\guanylate cyclase pathway, the putative gap junction inhibitor carbenoxolone had no effect on bradykinin-induced relaxation, suggesting that gap junctions play little or no role in the relaxation mediated by NO. However, when the NO\ guanylate cyclase pathway was inhibited, so that the relaxation obtained in response to bradykinin could be attributed to an EDHF-like mechanism [1] , carbenoxolone significantly inhibited relaxation, suggesting that gap junctions may play some role in transmitting the response to EDHF in these arteries. The identity of the EDHF in this tissue is unknown but, in common with a number of other vascular tissues [14] [15] [16] [17] , its action is sensitive to the K + channel blockers apamin and charybdotoxin [1] , which block the calcium-sensitive K + channels SK Ca (small conductance) and BK Ca (big conductance) respectively [18, 19] , and is therefore consistent with the current dogma that these channels play an important role in mediating the hyperpolarization. If these channels are present on the endothelium, then hyperpolarization within the endothelium may spread via carbenoxolone-sensitive myoendothelial gap junctions together with gap junctions between the smooth muscle cells. Alternatively, if bradykinin induces the release of a diffusible EDHF, then activation of SK Ca and BK Ca may be responsible for hyperpolarization of discreet smooth muscle cells, from which current spreads electronically via carbenoxolone-sensitive gap junctions between smooth muscle cells.
In this tissue the EDHF mechanism does not normally appear to play a role in bradykinin-mediated relaxation, but is exposed when NO\guanylate cyclase is inhibited [1] . It is possible that the NO\guanylate cyclase pathway provides intrinsic inhibition of the EDHF mechanism in this tissue, and that removal of this inhibition upregulates the EDHF mechanism, which compensates for the loss of the NO\guanylate cyclase pathway. Several studies suggest that normal NO\cGMP levels within the endothelial cells may inhibit EDHF synthesis and\or release [20] [21] [22] [23] . Since the present study shows that gap junctions are only involved in bradykinin-induced relaxation when NO\guanylate cyclase has been removed, and because it has been reported that cGMP-dependent phosphorylation of connexins inhibits gap junctions [24] , it is possible that part of the intrinsic inhibition of the EDHF pathway is at the level of gap junctions.
Although inhibition of the NO\guanylate cyclase pathway results in bradykinin-induced relaxation mediated by an EDHF-like mechanism, ODQ, L-NAME and hydroxocobalamin do not produce identical effects [1] . The present study confirms a previous report that the soluble guanylate cyclase inhibitor ODQ does not alter tissue sensitivity to bradykinin, whereas inhibition\ removal of NO lowers the tissue sensitivity [1] . We have suggested previously that one possible explanation for this observation is that inhibition of guanylate cyclase results in a more effective removal of the proposed inhibition imposed by cGMP-dependent processes than scavenging or inhibiting the synthesis of NO. This would allow a greater up-regulation of the EDHF mechanism, including the component mediated by gap junctions. This would explain why the greatest effect of the gap junction inhibitor can be seen in the presence of the soluble guanylate cyclase inhibitor ODQ. Indeed, we have shown that the reduced tissue sensitivity to bradykinin in the presence of hydroxocobalamin is abrogated by ODQ [1] . Similarly, differences between L-NAME and hydroxocobalamin may be due to their different abilities to lower NO and up-regulate the EDHF mechanism [1] .
In conclusion, the data suggest that carbenoxolonesensitive gap junctions are not normally required for the bradykinin-induced relaxation of supernumerary arteries in vitro, but play an important role in mediating the EDHF-like response to bradykinin that is exposed when the NO\guanylate cyclase pathway is inhibited.
